Patient demographic and clinical characteristics assessed at baseline (meaning the initiation of ICI therapy) included age, sex, body mass index (BMI), dyslipidemia (any type) and Diabetes Mellitus, Eastern Cooperative Oncology Group (ECOG) performance status, histological features, number and sites of metastasis at baseline, presence of EGFR mutations or ALK rearrangements, and PD-L1 status. Here, EGFR is linked to metabolic syndrome.